High Concordance Between Immunohistochemistry and Fluorescence in Situ Hybridization Testing for HER2 Status in Breast Cancer Requires a Normalized IHC Scoring System

Modern Pathology - United Kingdom
doi 10.1038/modpathol.2008.83
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Review of HER2 Immunohistochemistry and in Situ Hybridisation Concordance in Breast Cancer

Pathology
Forensic MedicinePathology
2020English

Comparison of Immunohistochemistry and Fluorescence in Situ Hybridization for the Analysis of Her2/Neu and Topoisomerase Ii-Alpha Status in Human Breast Cancer

Turk Patoloji Dergisi
Forensic MedicinePathology
2010English

Assessment of HER2 Status in Breast Cancer: Overall Positivity Rate and Accuracy by Fluorescence in Situ Hybridization and Immunohistochemistry in a Single Institution Over 12 Years: A Quality Control Study

BMC Cancer
Cancer ResearchOncologyGenetics
2013English

Necessity of in Situ Hybridization Test of Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Patients With Equivocal HER2 Immunohistochemistry Results

Journal of Breast Disease
2018English

Macrodissection Prior to Closed System RT-qPCR Is Not Necessary for Estrogen Receptor and HER2 Concordance With IHC/FISH in Breast Cancer

Laboratory Investigation
Forensic MedicinePathologyCell BiologyMolecular Biology
2018English

Electron Microscopic Basis for Applications of Immunohistochemistry (IHC) and in Situ Hybridization (ISH) to Diagnostic Pathology.

Acta Histochemica et Cytochemica
Cell BiologyBiochemistryHistologyForensic MedicinePathologyPhysiology
1995English

Expression of HER2 and the Coamplified Genes GRB7 and MLN64 in Human Breast Cancer: Quantitative Real-Time Reverse Transcription-PCR as a Diagnostic Alternative to Immunohistochemistry and Fluorescence in Situ Hybridization

Clinical Cancer Research
Cancer ResearchOncology
2005English

Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study

European Journal of Breast Health
2018English

HER2-HER3 Dimer Quantification by FLIM-FRET Predicts Breast Cancer Metastatic Relapse Independently of HER2 IHC Status

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy